adenovirus-p53 transduced dendritic cell vaccine + ex vivo expanded T-lymphocytes

This is a combination immunotherapy approach consisting of two components. The first component is a dendritic cell (DC) vaccine created by infecting autologous dendritic cells with an adenoviral vector carrying the wild-type p53 gene. The second component involves ex vivo expansion of tumor-infiltrating lymphocytes (TILs). The p53-DC vaccine works by transducing the patient's dendritic cells with adenovirus containing wild-type p53, which then present p53 epitopes to activate T cells against tumor cells expressing mutated p53. This approach is particularly relevant since p53 mutations and protein overexpression are present in many cancer types, making p53 an attractive target for immunotherapy. The ex vivo expanded T-lymphocytes component involves collecting TILs from tumor tissue, expanding them in laboratory conditions, and then reinfusing them to enhance anti-tumor immune responses.

Other names

autologous dendritic cells transduced with wild-type p53 adenovirus vaccine + ex vivo expanded T-lymphocytes